B&C helps Aptamer's highly successful £4.275m fundraising

30/03/2026

We're delighted to have helped Aptamer Group with its successful £4.275m Placing and Subscription which, alongside a separate £0.5m retail offer, aims to bolster working capital, support AI-enabled discovery, and fund in-vivo development for liver fibrosis and radiopharmaceutical programs. 

Aptamer Group is a leading developer of next-generation synthetic binders delivering innovation to the life sciences industry. The Group develops Optimer® binders, advanced molecules that work like antibodies by attaching to specific targets in the body. These binders are used in medicine, diagnostic tests, and research tools, offering benefits like high stability, reliable performance, and lower costs compared to traditional antibodies.

This fundraising, which received strong support from both existing and new investors, will primarily fund growth initiatives, including the development of an AI model for RNA-binding proteins and transcription factors, and generating in-vivo data for a radiopharmaceutical program.

Our thanks to our wonderful clients at company and advisors Spark Advisory Partners.

If you'd like to find out how we can help ensure the success of your fundraisings, chat with us today: hello@blackandcallow.com

Back to News